Trandolapril With Verapamil Hydrochloride
Recommended · restricted CardiovascularRestrictedNot applicable line
Treatment of hypertension in patients who are not adequately controlled with 4 mg of trandolapril monotherapy.
2
Submissions
1 resub
2005–06
On the record
—
ICER range
Cost-min
Cost basis
Access path
- Nov 2005Not recommended
lack of clinical need in patients with hypertension for the combination, concerns about inappropriate substitution for…
- ↻ resubmittedNov 2006Recommended · restricted
Comparator changed: trandolapril and verapamil SR used concomitantly, and individually →…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER range calculated
The PBAC recommended listing on a cost-minimisation basis compared with the corresponding strengths of the trandolapril and verapamil hydrochloride sustained release constituents. PBAC · 2006
Decision context
PopulationPatients with mild to moderate essential hypertension who are not adequately controlled with 4 mg of trandolapril monotherapy, stabilised on both trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2006 | Recommended · restricted | trandolapril monotherapy and verapamil-SR monotherapy | — | RCT · DBP |
| Nov 2005 | Not recommended | trandolapril and verapamil SR used concomitantly, and individually | — | RCT · Diastolic BP reduction |